Statistiche di base
| LEI | 549300F55SN4ZR2OA180 |
| CIK | 1604950 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to scPharmaceuticals Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 25, 2025 |
scPharmaceuticals Employee Q&A EX-99.1 Exhibit 99.1 scPharmaceuticals Employee Q&A General Information 1. What was announced regarding scPharmaceuticals and MannKind? • scPharmaceuticals and MannKind have entered into a definitive merger agreement for MannKind to acquire scPharmaceuticals. • Under and subject to the terms of the merger agreement, MannKind and its newly-formed acquisition subsidiary will commence a tender offer |
|
| August 25, 2025 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among MANNKIND CORPORATION, SEACOAST MERGER SUB, INC. and scPHARMACEUTICALS INC. Dated as of August 24, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Certain Interpretations. 14 ARTICLE II THE OFFER 15 2.1 The Offer 15 2.2 Company Actions 17 ARTICLE III THE MERGER 18 |
|
| August 25, 2025 |
EX-99.2 Exhibit 99.2 Project Seacoast John Communication to Employees Monday, August 25, 2025, 7:31 a.m. ET John email to employees Cc Mike C. so he can reply with his communication “This morning, we announced some very exciting news: scPharmaceuticals has entered into a definitive merger agreement for MannKind to acquire our company. Attached is the press release that was issued this morning. We |
|
| August 25, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 scPharmaceuticals Inc. (Name of Subject Company (Issuer)) Seacoast Merger Sub, Inc. (Offeror) an indirect wholly owned subsidiary of MannKind Corporation (Parent of Offeror) Common Stock, $0.0001 Par Value (Titl |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 24, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation or organizati |
|
| August 25, 2025 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases • Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unm |
|
| August 25, 2025 |
EX-10.1 Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. AMENDMENT 1 to Supply Agreement THIS AMENDMENT 1 (“Amendment”) to the Supply Agreement dated August 15, 2020 (the “Agreement”), as supplemented wit |
|
| August 25, 2025 |
EX-99.(a)(5)(C) Exhibit (a)(5)(C) Mannitarians, On behalf of the board of directors and leadership team I am excited to share a major milestone in MannKind’s journey: today we have entered into a definitive merger agreement to acquire scPharmaceuticals, a company with deep expertise in cardiorenal care and a shared commitment to patient-centric innovation. This acquisition marks a pivotal moment f |
|
| August 25, 2025 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 scPharmaceuticals Inc. (Name of Subject Company) scPharmaceuticals Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 810648105 (CUSIP |
|
| August 25, 2025 |
MannKind Corporation Investor Call EX-99.(a)(5)(F) Exhibit (a)(5)(F) MannKind Corporation Investor Call Operator: Good morning and welcome to the MannKind Corporation’s call to discuss its acquisition of scPharmaceuticals. The call will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and will be available for approximately 90 days. During the course of this call, management ma |
|
| August 25, 2025 |
MannKind Corporate Announcement EX-99.(a)(5)(E) Exhibit (a)(5)(E) MannKind Corporate Announcement LINKEDIN August 25, 2025 MannKind has announced the signing of a definitive merger agreement to acquire scPharmaceuticals. This acquisition marks MannKind’s strategic expansion into cardiorenal medicine, establishing the company’s cardiometabolic business alongside its orphan lung division. You can read more information about this e |
|
| August 25, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 scPharmaceuticals Inc. (Name of Subject Company (Issuer)) Seacoast Merger Sub, Inc. (Offeror) an indirect wholly owned subsidiary of MannKind Corporation (Parent of Offeror) Common Stock, $0.0001 Par Value (Titl |
|
| August 25, 2025 |
EX-99.(a)(5)(D) Exhibit (a)(5)(D) Dear scPharmaceuticals Team, As we announce our intent to join forces, I want to take a moment to acknowledge the significance of this moment and share a few thoughts directly with you. At MannKind, we are driven by a shared aspiration to improve the lives of people with serious unmet medical needs. As we look ahead, we see tremendous opportunity in bringing our t |
|
| August 25, 2025 |
EX-99.3 Exhibit 99.3 Via email Dear [vendor], We are pleased to share that MannKind Corporation has agreed to acquire scPharmaceuticals. The transaction is expected to close in the fourth quarter, subject to the satisfaction of customary closing conditions and the receipt of transaction-related regulatory approvals. This combination will help accelerate the growth of FUROSCIX, expanding its reach |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| August 25, 2025 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 scPharmaceuticals Inc. (Name of Subject Company) scPharmaceuticals Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 810648105 (CUSIP |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; d |
|
| August 7, 2025 |
Inventory Research and Development Costs Selling, General, and Administrative Costs 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS I |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission F |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation or organization) |
|
| May 14, 2025 |
Inventory Research and Development Costs Selling, General, and Administrative Costs 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2025 |
Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than |
|
| April 21, 2025 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 21, 2025 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 19, 2025 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 19, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission F |
|
| March 19, 2025 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.6 SCPHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of scPharmaceuticals Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees o |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 S-8 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
scPharmaceuticals Inc. Policy and Procedures on Insider Trading and Disclosure Exhibit 19.1 SCPHARMACEUTICALS INC. POLICY AND PROCEDURES ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of scPharmaceuticals Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Policy and Procedures on Insider Trading and Disclosure (the “Ins |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38293 SCPHARMACEUTI |
|
| March 19, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCPHARMACEUTICALS INC. |
|
| January 10, 2025 |
Exhibit 99.1 scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unau |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2024 |
SCPH / scPharmaceuticals Inc. / KING LUTHER CAPITAL MANAGEMENT CORP - SC 13G/A Passive Investment SC 13G/A 1 d863545dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* scPharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 810648105 (CUSIP Number) November 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 14, 2024 |
SCPH / scPharmaceuticals Inc. / Lundbeckfond Invest A/S - SC 13G/A Passive Investment SC 13G/A 1 tm2427620d16sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ScPharmaceuticals Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 810648105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement |
|
| November 14, 2024 |
EX-99.1 2 tm2427620d16ex1.htm EXHIBIT 1 EXHIBIT 1 Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of scPharmaceuticals Inc. Date: November 14, 2024 LUNDBECKFOND INVEST A/S By |
|
| November 14, 2024 |
SCPH / scPharmaceuticals Inc. / LYTTON LAURENCE W Passive Investment SC 13G/A 1 scph13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* scPharmaceuticalsInc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 810648105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTIC |
|
| November 13, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2024 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million |
|
| October 30, 2024 |
SCPH / scPharmaceuticals Inc. / KING LUTHER CAPITAL MANAGEMENT CORP - SC 13G/A Passive Investment SC 13G/A 1 d900099dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* scPharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 810648105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| August 15, 2024 |
EX-99.1 2 ss3752792ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 5 to Schedule 13D, dated August 13, 2024 (the “Schedule 13D”), with respect to the common stock, par value $0.0001 per share, of scPharmaceuticals Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance wit |
|
| August 15, 2024 |
SCPH / scPharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* scPharmaceuticals Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 810648105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-64 |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2024 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and posi |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS I |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2024 |
12,000,000 Shares of Common Stock Pre-funded Warrants to Purchase 500,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277886 PROSPECTUS SUPPLEMENT (To Prospectus dated March 22, 2024) 12,000,000 Shares of Common Stock Pre-funded Warrants to Purchase 500,000 Shares of Common Stock We are offering up to 12,000,000 shares of our common stock, par value $0.0001 per share, at a price of $4.00 per share. We are also offering to select investors, in |
|
| August 13, 2024 |
EX-1.1 2 d875997dex11.htm EX-1.1 Exhibit 1.1 12,000,000 Shares Pre-Funded Warrants to Purchase 500,000 Shares of Common Stock scPharmaceuticals Inc. UNDERWRITING AGREEMENT August 12, 2024 Leerink Partners LLC TD Securities (USA) LLC As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State St Boston, MA 02110 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New Yo |
|
| August 13, 2024 |
Exhibit 4.1 scPharmaceuticals Inc. WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ⚫ ] (subject to adjustment) Warrant No. CS–[ ⚫ ] Original Issue Date: August 13, 2024 scPharmaceuticals Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ⚫ ] or its registered assign |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2024 |
Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUC |
|
| August 12, 2024 |
Exhibit 10.2 Revenue Participation Right Purchase and Sale Agreement By and Between s and Perceptive Credit Holdings IV, LP Dated as of August 9, 2024 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Accounting Terms and Principles 27 Section 1.3 Certain Interpretations 28 Section 1.4 29 Section 1.5 Headings 29 ARTICLE 2 PURCHASE, SALE AND ASSIGNMENT OF THE REVE |
|
| August 12, 2024 |
Subject to Completion, dated August 12, 2024 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277886 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| August 12, 2024 |
Exhibit 10.1 CREDIT AGREEMENT AND GUARANTY dated as of August 9, 2024 by and among SCPHARMACEUTICALS INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO as the Lenders, and PERCEPTIVE CREDIT HOLDINGS IV, LP, as the Administrative Agent U.S. $75,000,000 TABLE OF CONTENTS SECTION 1. DEFINITIONS 1 1.01 Certain |
|
| July 2, 2024 |
SCPH / scPharmaceuticals Inc. / KING LUTHER CAPITAL MANAGEMENT CORP - SC 13G/A Passive Investment SC 13G/A 1 d857065dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* scPharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 810648105 (CUSIP Number) June 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation or organization |
|
| May 20, 2024 |
SCPH / scPharmaceuticals Inc. / KING LUTHER CAPITAL MANAGEMENT CORP - SC 13G Passive Investment SC 13G 1 d834770dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* scPharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 810648105 (CUSIP Number) May 17, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 20, 2024 |
EX-99.1 2 d834770dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of t |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2024 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host investor conference call and webcast today, Tuesda |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 29, 2024 |
SCPH / scPharmaceuticals Inc. / LYTTON LAURENCE W Passive Investment SC 13G 1 scph13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* scPharmaceuticalsInc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 810648105 (CUSIP Number) April 17, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| April 26, 2024 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 26, 2024 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 12, 2024 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 22, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-277886 PROSPECTUS SUPPLEMENT (To Prospectus dated March 22, 2024) $50,000,000 Common Stock We have entered into a Sales Agreement with Cowen and Company, LLC, or TD Cowen, dated March 23, 2021, as amended and restated on March 13, 2024 (as the same may be amended, supplemented and/or restated from time to time), or |
|
| March 20, 2024 |
SCPHARMACEUTICALS INC. 25 Burlington Mall Road, Suite 203 Burlington, Massachusetts 01803 SCPHARMACEUTICALS INC. 25 Burlington Mall Road, Suite 203 Burlington, Massachusetts 01803 March 20, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Daniel Crawford Re: scPharmaceuticals Inc. Registration Statement on Form S-3 Filed March 13, 2024 File No. 333-277886 To the addressee set for |
|
| March 13, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement on Form S-3 (Form Type) scPharmaceuticals Inc. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38293 SCPHARMACEUTI |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| March 13, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 SCPHARMACEUTICALS INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION scPharmaceuticals Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Poli |
|
| March 13, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCPHARMACEUTICALS INC. |
|
| March 13, 2024 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.6 SCPHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of scPharmaceuticals Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees o |
|
| March 13, 2024 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provide |
|
| March 13, 2024 |
Exhibit 1.2 SCPHARMACEUTICALS INC. UP TO $50,000,000 SHARES OF COMMON STOCK AMENDED AND RESTATED SALES AGREEMENT March 13, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: scPharmaceuticals Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“TD Cowen”), are parties to that certain Sales Agreement dated March 23, 2021 (the “Original Ag |
|
| March 13, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission F |
|
| March 13, 2024 |
Exhibit 4.2 SCPHARMACEUTICALS INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishm |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| February 14, 2024 |
SCPH / scPharmaceuticals Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-scph123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCPHARMACEUTICALS INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
SCPH / scPharmaceuticals Inc. / 5AM Ventures IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245429d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648 105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 12, 2024 |
SCPH / scPharmaceuticals Inc. / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* scPharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 7, 2024 |
SCPH / scPharmaceuticals Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 SCPHARMACEUTICALS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* scPHarmaceuticals Inc. (Name of Issuer) common stock (Title of Class of Securities) 810648105 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 12, 2024 |
SCPH / scPharmaceuticals Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SCPHARMACEUTICALS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 810648105 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| January 4, 2024 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4 Inventory levels at the end of Q4 2023 c |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTIC |
|
| November 8, 2023 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., November 8, 2023 (GLOBE NEWSWIRE) – scPha |
|
| November 8, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commissi |
|
| September 20, 2023 |
Exhibit 10.1 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT, dated as of this 31st day of August, 2023 (“Sublease”), between 89 DEGREES, INC. (d/b/a Iris Concise), a Delaware corporation, having an office at c/o Iris USA, Inc., 112 Krog Street, Suite 26, Atlanta, GA 30307 (“Sublandlord”), and SCPHARMACEUTICALS INC., a Delaware corporation having an office at 2400 District Ave, Suite 310, Burlington, M |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2023 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today, Thursday, August 10, at 4:30pm ET BURLINGTON, Mass., August 10, 2023 (GLOBE NEWSWIRE) |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS I |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation or organization) |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor conference call and webcast today, Wednesday, Ma |
|
| April 27, 2023 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 27, 2023 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 22, 2023 |
Power of Attorney (included on signature page) S-8 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No. |
|
| March 22, 2023 |
EX-FILING FEES Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2023 Employ |
|
| March 22, 2023 |
Exhibit 10.5 SCPHARMACEUTICALS INC. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN Section 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the scPharmaceuticals Inc. 2023 Employment Inducement Award Plan (the “Plan”). The purpose of the Plan purpose is to enhance the ability of scPharmaceuticals Inc. (the “Company”) to attract, retain and motivate persons who are expected to make import |
|
| March 22, 2023 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash equivalents, restricted cash a |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission F |
|
| March 22, 2023 |
Exhibit 10.11 SCPHARMACEUTICALS INC. EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 16th day of November, 2017, between scPharmaceuticals Inc., a Delaware corporation (the “Company”), and John H. Tucker (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registrati |
|
| March 22, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCPHARMACEUTICALS INC. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from- to Commission File Number 001-38293 SCPHARMACEUT |
|
| March 22, 2023 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.6 SCPHARMACEUTICALS INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATIONPOLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of scPharmaceuticals Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or |
|
| March 22, 2023 |
Power of Attorney (included on signature pages below) S-8 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No. |
|
| March 13, 2023 |
SCPH / scPharmaceuticals Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SCPHARMACEUTICALS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 810648105 (CUSIP Number) MARCH 9, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission F |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 scPHarmaceuticals Inc. (Name of Issuer) common stock (Title of Class of Securities) 810648105 (CUSIP Number) February 16, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 15, 2023 |
SCPH / Scpharmaceuticals Inc / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 SCPHARMACEUTICALS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2023 |
SCPH / Scpharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-scph123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SCPHARMACEUTICALS INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 14, 2023 |
SCPH / Scpharmaceuticals Inc / 5AM Ventures IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236172d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648 105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commissio |
|
| November 29, 2022 |
SCPH / Scpharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* scPharmaceuticals Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 810648105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-64 |
|
| November 29, 2022 |
Final Form Form of Lock-up Agreement SVB Securities LLC Cowen and Company, LLC As Representatives of the Several Underwriters c/o SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 and Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 RE: scPharmaceuticals Inc. |
|
| November 29, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| November 25, 2022 |
SCPH / Scpharmaceuticals Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SCPHARMACEUTICALS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 810648105 (CUSIP Number) November 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| November 23, 2022 |
EX-1.1 2 d240360dex11.htm EX-1.1 Exhibit 1.1 6,620,000 Shares Pre-Funded Warrants to Purchase 2,905,000 Shares of Common Stock scPharmaceuticals Inc. UNDERWRITING AGREEMENT November 22, 2022 SVB SECURITIES LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o SVB SECURITIES LLC 53 State Street, 40th Floor Boston, MA 02109 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New |
|
| November 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commissio |
|
| November 23, 2022 |
Exhibit 4.1 scPharmaceuticals Inc. WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ? ] (subject to adjustment) Warrant No. [ ? ] Original Issue Date: November 25, 2022 scPharmaceuticals Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER] or its registered assi |
|
| November 23, 2022 |
6,620,000 Shares of Common Stock Pre-funded Warrant to Purchase 2,905,000 Shares of Common Stock 424B5 1 d404036d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254637 PROSPECTUS SUPPLEMENT (To Prospectus dated April 29, 2021) 6,620,000 Shares of Common Stock Pre-funded Warrant to Purchase 2,905,000 Shares of Common Stock We are offering 6,620,000 shares of our common stock, par value $0.0001 per share, at a price of $5.25 per share. We are also offerin |
|
| November 22, 2022 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated November 22, 2022 Relating to Preliminary Prospectus Supplement Dated November 21, 2022 Registration Statement No. |
|
| November 21, 2022 |
Subject to Completion, dated November 21, 2022 424B5 1 d404036d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254637 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2022 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self- administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Entered into a secured debt financing agreement for up to $100 million with funds |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTIC |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commission |
|
| October 14, 2022 |
Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT AND GUARANTY dated as of October 13, 2022 by and among SCPHARMACEUTICALS INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO as the Lenders, and OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent U.S. $100,000,000 TABLE OF CONTENTS SECTION 1. DEFINIT |
|
| October 14, 2022 |
Exhibit 4.1 SCHEDULE OF WARRANT HOLDERS In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Holder Number of Shares of Common Stock INPRS Strategic Credit Holdings, LLC 7,966 Oaktree Gilead Investment Fund AIF (Delaware), L.P. 34,226 Oaktree Specialty Lending C |
|
| August 15, 2022 |
SCPH / Scpharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* SCPHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2022 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update Announced FDA acceptance of FUROSCIX? New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of an anticipated Q4 2022 launch of FUROSCIX, if approved Ended Q2 with cash, cash equivalent |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC |
|
| July 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction (Commission (IRS Employe |
|
| July 12, 2022 |
Exhibit 99.1 scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure Study results favor FUROSCIX? versus ?treatment as usual? in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability profile Company on track for Q4 2022 commercial launch of FUROSCIX, if approved BURLINGTON, Mass. ? July 12, 2022 ? |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction (Commission (IRS Employe |
|
| May 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?Amendment?) is made and entered into as of April 11, 2022 (the ?Effective Date?), by and between NEEP INVESTORS HOLDINGS LLC, a Delaware limited liability company (?Landlord?), and SCPHARMACEUTICALS INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Office Lease Agreement da |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2022 |
Exhibit 99.1 scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX? New Drug Application PDUFA action date set for October 8, 2022 Company preparing for Q4 commercial launch, if approved BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) ? scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the d |
|
| May 16, 2022 |
Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX?, if approved Ended Q1 with cash, cash equivalents, restricted cash and investments of $65.6 million BURLINGTON, Mass., May 16, 202 |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS IN |
|
| April 28, 2022 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 12, 2022 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application Anticipates Q4 2022 commercial launch, if approved BURLINGTON, Mass. – April 11, 2022 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and |
|
| April 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Comm |
|
| March 22, 2022 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation scPharmaceuticals Securities Corporation Massachusetts |
|
| March 22, 2022 |
As filed with the Securities and Exchange Commission on March 22, 2022 As filed with the Securities and Exchange Commission on March 22, 2022 Registration No. |
|
| March 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2022 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Commission |
|
| March 22, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) scPharmaceuticals Inc. |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from- to Commission File Number 001-38293 SCPHARMACEUTIC |
|
| March 22, 2022 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Successfully completed all testing; plan to re-submit FUROSCIX? NDA by April 15, 2022 Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved Presented key FREEDOM-HF secondary endpoint data at the Cardiovascular Research |
|
| February 18, 2022 |
SCPH / Scpharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)*1 SCPHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* SCPHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| February 14, 2022 |
SCPH / Scpharmaceuticals Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 9, 2021 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date FUROSCIX? NDA resubmission anticipated for Q1 2022 due to COVID-19 related global supply chain logistics interruptions and travel restrictions Revised NDA resu |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICAL |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Commissi |
|
| September 10, 2021 |
Exhibit 99.1 scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021 Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX? versus a historical comparator group Company on track to resubmit FUROSCIX NDA in the fourth |
|
| September 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) ( |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) 001-38293 Delaware 46-5184075 (Commission File Number) (State or other jurisdiction of incorporation or |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC |
|
| August 11, 2021 |
scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX? NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4 Announced positive top-line results from the FREEDOM-HF study demonstrating th |
|
| July 14, 2021 |
Exhibit 99.1 scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study Reduced average 30-day heart failure related costs by $17,753 (p<0.0001) per study subject in FUROSCIX? arm compared to historically matched comparators Study halted early due to highly statistically significant reduction in 30-day heart failure-related costs observed during the prespecified interim analy |
|
| July 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Commi |
|
| July 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction (Commission (IRS Employer |
|
| July 1, 2021 |
Exhibit 99.1 scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX? FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time FUROSCIX NDA resubmission targeted for Q4 2021 BURLINGTON, Mass. ? July 1, 2021 ? scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutica |
|
| June 9, 2021 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2021 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Commission F |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS IN |
|
| May 12, 2021 |
Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) ? scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2021 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Commission F |
|
| April 27, 2021 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def |
|
| April 27, 2021 |
scPharmaceuticals Inc. 2400 District Avenue, Suite 310 Burlington, MA 01803 scPharmaceuticals Inc. 2400 District Avenue, Suite 310 Burlington, MA 01803 April 27, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: scPharmaceuticals Inc.: Registration Statement on Form S-3 filed March 23, 2021 (File No. 333- 254637) Ladies and Gentlemen: Pursuant to Rule 461 under the Sec |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 23, 2021 |
Form of Subordinated Indenture (including Form of Subordinated Note) Exhibit 4.3 SCPHARMACEUTICALS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| March 23, 2021 |
Sales Agreement, dated as of March 23, 2021 between the Registrant and Cowen and Company, LLC Exhibit 1.2 SCPHARMACEUTICALS INC. UP TO $50,000,000 SHARES OF COMMON STOCK SALES AGREEMENT March 23, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: scPharmaceuticals Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time |
|
| March 23, 2021 |
Exhibit 4.2 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock of scPharmaceuticals Inc. (?scPharma?, ?we?, ?our?) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Second Amended a |
|
| March 23, 2021 |
As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation or organization) (Commission |
|
| March 23, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation scPharmaceuticals Securities Corporation Massachusetts |
|
| March 23, 2021 |
Form of Senior Indenture (including Form of Senior Note) Exhibit 4.2 SCPHARMACEUTICALS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certific |
|
| March 23, 2021 |
Exhibit 99.1 scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update FUROSCIX? New Drug Application resubmission anticipated in Q3 2021 FREEDOM clinical study on track for topline results in Q3 2021 Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million, sufficient to fund operations through potential FUROSCIX |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from- to Commission File Number 001-38293 SCPHARMACEUTIC |
|
| March 12, 2021 |
Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF SCPHARMACEUTICALS INC. (the ?Corporation?) Section 8 of Article VI of the Amended and Restated By-laws of the Corporation (the ?By-laws?), is hereby amended and restated in its entirety to read as follows: ?SECTION 8. Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts. Unless the Corporation consents i |
|
| March 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2021 (March 9, 2021) SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) 001-38293 Delaware 46-5184075 (Commission File Number) (State or other jurisdiction of i |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 (February 23, 2021) scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction |
|
| February 23, 2021 |
EX-99.1 2 d138732dex991.htm EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million, sufficient to fund operations through potential FUROSCIX® approval and launch and |
|
| February 17, 2021 |
EX-99.1 2 d143096dex991.htm EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors BURLINGTON, Mass. – February 17, 2021 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 (February 16, 2021) scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SCPHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648 105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 (December 3, 2020) scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdictio |
|
| December 7, 2020 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX® CRL did not identify clinical deficiencies BURLINGTON, Mass. – December 7, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduc |
|
| December 4, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 (December 3, 2020) scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdictio |
|
| November 16, 2020 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update Commercialization preparedness activities continuing ahead of December 30 PDUFA date for FUROSCIX® (furosemide injection) for subcutaneous administration Enrolled first patient in FREEDOM-HF Phase 3 clinical trial Projected annual net loss for 2020 narrows to $34-37M BURLINGTON, Ma |
|
| November 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2020 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Com |
|
| November 16, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SUPPLY AGREEMENT This SUPPLY AGREEMENT (the “Agreement”) dated August 15, 2020 (the “Effective Date”), is between West Pharmace |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 scph-10q20200930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| August 20, 2020 |
Entry into a Material Definitive Agreement - 8-K 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2020 (August 15, 2020) SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) 001-38293 Delaware 46-5184075 (Commission File Number) (State or other jurisdicti |
|
| August 13, 2020 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update Preparations ongoing for December 30, 2020 FUROSCIX® PDUFA date BURLINGTON, Mass. – August 13, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused ther |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2020 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) 001-38293 Delaware 46-5184075 (Commission File Number) (State or other jurisdiction of incorporatio |
|
| July 27, 2020 |
Financial Statements and Exhibits, Other Events 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2020 (July 27, 2020) SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46- |
|
| July 27, 2020 |
EX-99.1 2 d85896dex991.htm EX-99.1 Exhibit 99.1 scPharmaceuticals Announces FDA Acceptance of FUROSCIX® New Drug Application Resubmission FDA sets PDUFA date of December 30, 2020 BURLINGTON, Mass. – July 27, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, |
|
| July 10, 2020 |
scPharmaceuticals Appoints Sara Bonstein to Board of Directors EX-99.1 2 d80734dex991.htm EX-99.1 Exhibit 99.1 scPharmaceuticals Appoints Sara Bonstein to Board of Directors BURLINGTON, Mass. – July 10, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced |
|
| July 10, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2020 (July 6, 2020) scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of in |
|
| June 10, 2020 |
EX-3.1 2 d942891dex31.htm EX-3.1 Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF SCPHARMACEUTICALS INC. (the “Corporation”) Section 8 of Article VI of the Amended and Restated By-laws of the Corporation (the “By-laws”), is hereby amended and restated in its entirety to read as follows: “SECTION 8. Exclusive Jurisdiction of Delaware Courts or the United States District Court for the Di |
|
| June 10, 2020 |
8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2020 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Commissi |
|
| June 3, 2020 |
SCPH / scPharmaceuticals Inc. / Sun Pharmaceutical Industries Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 26, 2020 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| May 26, 2020 |
SCPH / scPharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th Floor New York, NY |
|
| May 22, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 (May 20, 2020) SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-38293 46-5184075 (State or other jurisdiction of incorporation) (Comm |
|
| May 22, 2020 |
EX-1.1 2 d925586dex11.htm EX-1.1 Exhibit 1.1 Execution Version 5,780,347 Shares scPharmaceuticals Inc. UNDERWRITING AGREEMENT May 20, 2020 JEFFERIES LLC SVB LEERINK LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB LEERINK LLC One Federal Street, 37th Floor Boston, MA 02110 Ladies and Gentlemen: Introductory. scPharmaceuticals |
|
| May 22, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229120 PROSPECTUS SUPPLEMENT (To prospectus dated February 11, 2019) 5,780,347 Shares Common Stock We are offering 5,780,347 shares of our common stock, par value $0.0001 per share, at a price of $8.65 per share. Our common stock is listed on The Nasdaq Global Select Market under the symbol “SCPH.” On May 20, 2020, the c |
|
| May 20, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229120 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2020 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Commissi |
|
| May 12, 2020 |
EX-99.1 2 d912542dex991.htm EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2020 Financial Results and Provides Business Update Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Strong balance sheet with over $75M in cash Projected annual loss for 2020 narrows to $36-40M BURLINGTON, Mass., May 12, 2020 (BUSINESSWIRE) – scPharmaceuticals Inc. (Nasdaq: SCPH), |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS IN |
|
| April 27, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2020 |
Exhibit 99.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Michael Levitt, Jeremy Barr and Evgeniya Berezkina, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in connection with the undersigned’s beneficial ownership of, or participation in a |
|
| March 31, 2020 |
SCPH / scPharmaceuticals Inc. / Sun Pharmaceutical Industries Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 27, 2020 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| March 27, 2020 |
SCPH / scPharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| March 24, 2020 |
Subsidiaries of the Registrant EX-21.1 4 scph-ex211184.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation scPharmaceuticals Securities Corporation Massachusetts |
|
| March 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from- to Commission File Number 001-38293 SCPHARMACEUTIC |
|
| March 24, 2020 |
EX-10.9 3 scph-ex109186.htm EX-10.9 Exhibit 10.9 SCPHARMACEUTICALS INC. EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 12th day of December 2019 (the “Effective Date”), between scPharmaceuticals Inc., a Delaware corporation (the “Company”), and Rachael Nokes (the “Executive”). WHEREAS, the Company and the Executive are parties to an offer letter, dated June 18, 2014 |
|
| March 24, 2020 |
Description of Registered Securities EX-4.2 2 scph-ex42185.htm EX-4.2 Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock of scPharmaceuticals Inc. (“scPharma”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, |
|
| March 24, 2020 |
SCPH / scPharmaceuticals Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on March 24, 2020 Registration No. |
|
| March 24, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d895467d8k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2020 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-382 |
|
| March 24, 2020 |
EX-99.1 2 d895467dex991.htm EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Initiating FUROSCIX pre-commercialization and product positioning efforts Strong balance sheet; ending 2019 with $72.8 million in cash Guiding 2020 quarterly GAAP exp |
|
| March 23, 2020 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT March 23, 2020 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includ |
|
| March 23, 2020 |
SCPH / scPharmaceuticals Inc. / Ikarian Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* scPharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) March 11, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2020 |
SCPH / scPharmaceuticals Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCPHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 810648105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2019 SCPHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-38293 46-5184075 (Com |
|
| November 12, 2019 |
EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies Completed $20.0 million term loan with Solar Capital Ltd. and Silicon Valley Bank; |
|
| November 12, 2019 |
SCPH / scPharmaceuticals Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICAL |
